scholarly journals The eIF2-alpha kinase HRI is a novel therapeutic target in multiple myeloma

2017 ◽  
Vol 55 ◽  
pp. 23-32 ◽  
Author(s):  
Nicholas Burwick ◽  
Michael Y. Zhang ◽  
Pilar de la Puente ◽  
Abdel Kareem Azab ◽  
Teresa S. Hyun ◽  
...  
Leukemia ◽  
2013 ◽  
Vol 28 (3) ◽  
pp. 680-689 ◽  
Author(s):  
J Minami ◽  
R Suzuki ◽  
R Mazitschek ◽  
G Gorgun ◽  
B Ghosh ◽  
...  

2014 ◽  
Vol 20 (22) ◽  
pp. 5796-5807 ◽  
Author(s):  
Arianna Ferrucci ◽  
Michele Moschetta ◽  
Maria Antonia Frassanito ◽  
Simona Berardi ◽  
Ivana Catacchio ◽  
...  

2008 ◽  
Vol 141 (5) ◽  
pp. 659-671 ◽  
Author(s):  
Yutaka Okawa ◽  
Teru Hideshima ◽  
Hiroshi Ikeda ◽  
Noopur Raje ◽  
Sonia Vallet ◽  
...  

2012 ◽  
Vol 108 (1) ◽  
pp. 170-178 ◽  
Author(s):  
S Fujiwara ◽  
Y Kawano ◽  
H Yuki ◽  
Y Okuno ◽  
K Nosaka ◽  
...  

Oncotarget ◽  
2016 ◽  
Vol 7 (43) ◽  
pp. 70481-70493 ◽  
Author(s):  
Lisa J. Crawford ◽  
Gordon Anderson ◽  
Cliona K. Johnston ◽  
Alexandra E. Irvine

2019 ◽  
Vol 19 (10) ◽  
pp. e148-e149
Author(s):  
Emine Gulsen Gunes ◽  
Hadas Lewinsky ◽  
Domenico Viola ◽  
Enrico Caserta ◽  
Michael Rosenzweig ◽  
...  

Blood ◽  
2017 ◽  
Vol 129 (10) ◽  
pp. 1308-1319 ◽  
Author(s):  
Teru Hideshima ◽  
Francesca Cottini ◽  
Yoshihisa Nozawa ◽  
Hyuk-Soo Seo ◽  
Hiroto Ohguchi ◽  
...  

Key Points TP53RK confers poor prognosis in MM patients. TP53RK knockdown or inhibition by IMiDs triggers MM cell apoptosis, validating TP53RK as a novel therapeutic target in MM.


Sign in / Sign up

Export Citation Format

Share Document